Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2018 Mar 2;9:403. doi: 10.3389/fimmu.2018.00403

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study

Paola Queirolo 1, Beatrice Dozin 2, Anna Morabito 3, Barbara Banelli 3,4, Patrizia Piccioli 5, Cristiana Fava 1, Claudio Leo 1, Roberta Carosio 3, Stefania Laurent 6, Vincenzo Fontana 2, Pier Francesco Ferrucci 7, Chiara Martinoli 7, Emilia Cocorocchio 7, Angelo Battaglia 7, Paolo A Ascierto 8, Mariaelena Capone 8, Ester Simeone 8, Federica De Galitiis 9, Elena Pagani 9, Gian Carlo Antonini Cappellini 9, Paolo Marchetti 9,10, Michele Guida 11, Stefania Tommasi 11, Mario Mandalà 12, Barbara Merelli 12, Pietro Quaglino 13, Paolo Fava 13, Massimo Guidoboni 14, Massimo Romani 3, Francesco Spagnolo 1, Maria Pia Pistillo 3,*, the Italian Melanoma Intergroup (IMI)
PMCID: PMC5840259  PMID: 29531523

In the original article, affiliation number 9 was wrong. The correct affiliation 9 is “Istituto Dermopatico dell’Immacolata IDI-IRCCS, Rome, Italy”. This error does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES